



Resource impact statement

Resource impact

Published: 13 November 2019

www.nice.org.uk

Cancer Drugs Fund technology

NICE has recommended rucaparib for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults.

Rucaparib will be available to the NHS in line with the [managed access agreement](#) with NHS England. As part of this, NHS England and Clovis Oncology have a commercial access agreement that makes rucaparib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

The resource impact of rucaparib will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires when the final analysis of the overall-survival data from the ARIEL3 trial is available.. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England's [Appraisal and Funding of Cancer Drugs from July 2016 \(including the new Cancer Drugs Fund\) - A new deal for patients, taxpayers and industry](#).

It is estimated that around 1,350 people per year with platinum-sensitive epithelial ovarian fallopian tube or peritoneal cancer that has responded to platinum-based chemotherapy are eligible for treatment with rucaparib.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.